Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Insmed, Inc. stock logo
INSM
Insmed
$104.59
+1.7%
$84.68
$60.40
$106.83
$19.84B0.92.30 million shs3.69 million shs
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$28.27
+16.1%
$22.63
$8.71
$36.91
$21.00B-1.013.75 million shs6.14 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.02
-0.2%
$17.09
$12.47
$22.80
$18.37B0.610.32 million shs14.25 million shs
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$15.67
+0.9%
$16.56
$13.61
$30.36
$5.30BN/A29,015 shs6,883 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Insmed, Inc. stock logo
INSM
Insmed
+0.96%+7.00%+4.19%+46.54%+32.79%
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-4.09%+5.96%+23.15%+5.68%+157.23%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-2.32%-3.64%-5.61%+19.55%-6.07%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
-0.26%-1.02%-3.48%-6.11%+1,552,999,900.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Insmed, Inc. stock logo
INSM
Insmed
3.8065 of 5 stars
2.54.00.04.32.11.70.6
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.8541 of 5 stars
4.43.00.00.01.61.70.0
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.851 of 5 stars
4.64.00.00.01.61.71.3
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$108.073.32% Upside
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
2.79
Moderate Buy$34.6722.63% Upside
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
3.25
Buy$24.7154.32% Upside
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
3.00
Buy$22.3342.52% Upside

Current Analyst Ratings Breakdown

Latest TLX, INSM, SMMT, and TEVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/9/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
7/8/2025
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $111.00
7/3/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$23.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$44.00
7/1/2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$30.00
6/26/2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$24.00 ➝ $23.00
6/12/2025
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$22.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$100.00 ➝ $112.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$96.00 ➝ $110.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$99.00 ➝ $106.00
6/11/2025
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$90.00 ➝ $102.00
(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Insmed, Inc. stock logo
INSM
Insmed
$363.71M54.55N/AN/A$1.60 per share65.37
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
$700K29,993.26N/AN/A$0.53 per share53.34
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$16.54B1.11$3.28 per share4.88$4.74 per share3.38
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$516.72M10.26$0.11 per share136.35$1.12 per share13.99
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Insmed, Inc. stock logo
INSM
Insmed
-$913.77M-$5.95N/AN/AN/A-265.93%-446.98%-52.70%8/6/2025 (Estimated)
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$221.32M-$0.34N/AN/AN/AN/A-62.87%-51.61%8/5/2025 (Estimated)
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
-$1.64B-$1.15N/A6.090.97-7.74%45.44%6.95%7/30/2025 (Estimated)
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
$32.93MN/A0.0032.65N/AN/AN/AN/AN/A

Latest TLX, INSM, SMMT, and TEVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2025Q2 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10N/AN/AN/AN/AN/A
7/30/2025Q2 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.64N/AN/AN/A$4.34 billionN/A
5/8/2025Q1 2025
Insmed, Inc. stock logo
INSM
Insmed
-$1.36-$1.42-$0.06-$1.42$91.63 million$92.82 million
5/7/2025Q1 2025
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.47$0.52+$0.05$0.18$3.99 billion$3.89 billion
5/1/2025Q1 2025
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
-$0.10-$0.09+$0.01-$0.09N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/AN/AN/AN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/AN/AN/AN/AN/A
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Insmed, Inc. stock logo
INSM
Insmed
11.38
5.86
5.44
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
N/A
10.63
10.63
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.59
1.03
0.74
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
0.99
2.78
2.66

Institutional Ownership

CompanyInstitutional Ownership
Insmed, Inc. stock logo
INSM
Insmed
N/A
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
4.61%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,271189.71 million184.02 millionOptionable
Summit Therapeutics PLC stock logo
SMMT
Summit Therapeutics
110742.67 million112.14 millionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
36,8301.15 billion1.14 billionOptionable
Telix Pharmaceuticals Limited stock logo
TLX
Telix Pharmaceuticals
N/A338.38 millionN/AN/A

Recent News About These Companies

William Blair Has Negative Outlook of TLX FY2025 Earnings
Missing the first double on this biotech star
Gozellix Receives Permanent HCPCS Code
Telix shares jump 7% on big US news

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Insmed stock logo

Insmed NASDAQ:INSM

$104.59 +1.72 (+1.67%)
Closing price 04:00 PM Eastern
Extended Trading
$103.42 -1.18 (-1.12%)
As of 05:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Summit Therapeutics stock logo

Summit Therapeutics NASDAQ:SMMT

$28.27 +3.91 (+16.05%)
Closing price 04:00 PM Eastern
Extended Trading
$28.22 -0.05 (-0.18%)
As of 06:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$16.02 -0.03 (-0.16%)
Closing price 03:59 PM Eastern
Extended Trading
$15.96 -0.06 (-0.37%)
As of 05:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Telix Pharmaceuticals stock logo

Telix Pharmaceuticals NASDAQ:TLX

$15.67 +0.14 (+0.90%)
Closing price 03:56 PM Eastern
Extended Trading
$15.70 +0.03 (+0.16%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.